Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Westside Investment Management Inc.

Westside Investment Management Inc. lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.5% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,761 shares of the biopharmaceutical company’s stock after selling 395 shares during the quarter. Westside Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $366,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. Wetzel Investment Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. Finally, Fairman Group LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.0 %

NYSE:BMY opened at $40.06 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38. The stock has a fifty day simple moving average of $42.64 and a 200 day simple moving average of $47.97.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.05 EPS. Equities analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.99%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analysts Set New Price Targets

Several brokerages have issued reports on BMY. Barclays lowered their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, BMO Capital Markets reduced their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.